Teva launches authorized generic of Victoza

Teva is launching an authorized generic of Novo Nordisk’ s Victoza (liraglutide injection 1.8mg), in the United States.

“By launching an authorized generic for Victoza (liraglutide injection 1.8mg), we are providing patients with Type 2 diabetes another option for this important treatment,” said Ernie Richardsen, senior vice president, head of U.S. Commercial Generics at Teva. “In addition to strengthening Teva's diverse complex generics portfolio, we are providing the first generic GLP-1 product to the U.S. marketplace, demonstrating once again our ability to sustain a generics powerhouse.”

Victoza had annual sales of $1.656 billion as of April 2024, per IQVIA.

[Read more: Teva rolls out generic Nexavar tablets]

Liraglutide is an injectable prescription medicine used along with diet and exercise to lower blood sugar (glucose) in adults and children who are 10 years of age and older with Type 2 diabetes mellitus; and to reduce the risk of major cardiovascular events such as heart attack, stroke or death in adults with Type 2 diabetes mellitus with known heart disease.